1M6MYTD1Y5YMAX
Loading quotes...
Forecast
The analysts' average price target is €38.49 (-22.90%). The median is €50.06 (+0.28%).
| Buy |
4 |
| Hold |
11 |
| Sell |
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | Sep 2025 | |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | 0 | - |
| Net profit | -14.98M | - |
| EBITDA | -14.81M | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €827.94M |
Number of shares | 16.54M |
52-week high/low | €50.08 - €4.89 |
| Dividends | No |
Beta | 0.44 |
P/E ratio | -29.87 |
PEG ratio | -0.45 |
P/B ratio | 10.29 |
P/S ratio | 0.00 |
Company profile
| Name | RAPT Therapeutics Inc |
| CEO | Brian Russell Wong |
| Employees | 67 |
Discover assets
Shareholders of RAPT Therapeutics Inc also invest in the following assets
